Advertisement
Advertisement
ABCL
AbCellera Biologics Inc. Common Shares
12.18
USDSponsored
+1.06
+9.53%
Nov 03, 16:00 UTC -5
Closed
Pre-Market
12.10
-0.08
-0.70%
AbCellera Biologics Inc. Common Shares (ABCL) Earnings
ABCL Earnings Reports
Positive Surprise Ratio
ABCL beat 10 of 23 last estimates.
43%
Next Report
Next Week
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$6.38M
/-$0.17
Implied change from Q2 26 (Revenue/ EPS)
+57.61%
/-5.56%
Implied change from Q3 25 (Revenue/ EPS)
-28.72%
/-10.53%
AbCellera Biologics Inc. Common Shares earnings per share and revenue
On Aug 05, 2026, ABCL reported earnings of -0.18 USD per share (EPS) for Q2 26, missing the estimate of -0.14 USD, resulting in a -23.54% surprise. Revenue reached 4.05 million, compared to an expected 7.94 million, with a -48.99% difference. The market reacted with a +10.30% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.17 USD, with revenue projected to reach 6.38 million USD, implying an decrease of -5.56% EPS, and increase of 57.61% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Mirum Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.87
Surprise
-75.30%
Tarsus Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$2.78
Actual
-$0.78
Surprise
+72.00%
Denali Therapeutics Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.54
Actual
-$0.64
Surprise
-17.95%
Alamar Biosciences, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.19
Surprise
+12.96%
Amgen Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
$5.90
Actual
$6.45
Surprise
+9.16%
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Ultragenyx Pharmaceutical Inc.
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$1.13
Actual
-$1.15
Surprise
-1.83%
Arvinas, Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.71%
Oculis Holding AG Ordinary shares
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.42
Actual
-$0.30
Surprise
+28.03%
FAQ
What were AbCellera Biologics Inc. Common Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, AbCellera Biologics Inc. Common Shares reported EPS of -$0.18, missing estimates by -23.54%, and revenue of $4.05M, -48.99% below expectations.
How did the market react to AbCellera Biologics Inc. Common Shares's Q2 2026 earnings?
The stock price moved up 10.3%, changed from $5.92 before the earnings release to $6.53 the day after.
When is AbCellera Biologics Inc. Common Shares expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for AbCellera Biologics Inc. Common Shares's next earnings report?
Based on 7
analysts, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.17 and revenue of $6.38M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.